Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases 5-hydroxytryptamine (5-HT) levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
S-ACCESS was a randomized, double-blinded trial to compare the relative efficacy of sarpogrelate (100mg three times daily) and aspirin (81mg once daily) in 1510 patients with recent cerebral infarction. Patients were followed for 0.9 to 3.5 years. The primary endpoint was recurrence of cerebral infarction; relative safety was also assessed.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Sarpogrelate (MCI-9042)Drug
Intervention Desc: Sarpogrelate (MCI-9042) is an antiplatelet drug that decreases serotonin levels in platelets via a blockade of 5-HT2 receptors; it has been used in atherosclerotic peripheral arterial disease.
- Aspirin Drug
ARM 1: Kind: Experimental Label: Aspirin
- MCI-9042 Drug
ARM 1: Kind: Experimental Label: MCI-9042
- Allocation: Randomized
- Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
- Purpose: Prevention
- Endpoint: Safety/Efficacy Study
- Intervention: Parallel Assignment
Patients were randomly assigned to receive either sarpogrelate (100 mg three times daily) or aspirin (81 mg once daily).
|Type||Measure||Time Frame||Safety Issue|
|Secondary||Safety related events.|
|Primary||recurrence of cerebral infarction||No|
|Secondary||intracerebral hemorrhage, subarachnoid hemorrhage, undetermined stroke, transient ischemic attack, myocardial infarction, unstable angina, or vascular death|